Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies.

Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J.

Blood. 1996 Oct 15;88(8):3223-9.

2.

CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation (HSCT) for haematological malignancies.

Bahçeci E, Read EJ, Leitman S, Childs R, Dunbar C, Young NS, Barrett AJ.

Br J Haematol. 2000 Feb;108(2):408-14.

PMID:
10691874
3.

A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.

Cornelissen JJ, van der Holt B, Petersen EJ, Vindelov L, Russel CA, Höglund M, Maertens J, Schouten HC, Braakman E, Steijaert MM, Zijlmans MJ, Slaper-Cortenbach I, Boogaerts MA, Löwenberg B, Verdonck LF.

Exp Hematol. 2003 Oct;31(10):855-64.

PMID:
14550800
4.
6.

Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation.

Bittencourt H, Rocha V, Chevret S, Socié G, Espérou H, Devergie A, Dal Cortivo L, Marolleau JP, Garnier F, Ribaud P, Gluckman E.

Blood. 2002 Apr 15;99(8):2726-33.

7.

CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.

Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.

Biol Blood Marrow Transplant. 1997 Apr;3(1):11-7.

PMID:
9209736
8.

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?

Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Horton C, Millar B, Shepherd V, Tait D, Saso R, Rowland A, Long S, Mehta J.

Bone Marrow Transplant. 2000 Sep;26(5):489-96.

9.

Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.

Bornhäuser M, Theuser C, Soucek S, Hölig K, Klingebiel T, Blau W, Fauser A, Runde V, Schwinger W, Rutt C, Ehninger G.

Haematologica. 2000 Aug;85(8):839-47.

10.

CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.

O'Donnell PV, Jones RJ, Vogelsang GB, Seber A, Ambinder RF, Flinn I, Miller C, Marcellus DC, Griffin C, Abrams R, Braine HG, Grever M, Hess AD, Piantadosi S, Noga SJ.

Bone Marrow Transplant. 1998 Nov;22(10):947-55.

11.

Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.

Olivieri A, Offidani M, Montanari M, Ciniero L, Cantori I, Ombrosi L, Masia CM, Centurioni R, Mancini S, Brunori M, Leoni P.

Haematologica. 1998 Apr;83(4):329-37.

12.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

13.

Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.

Cao TM, Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS.

Cancer. 2001 Jun 15;91(12):2205-13.

PMID:
11413507
14.

Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.

Finke J, Brugger W, Bertz H, Behringer D, Kunzmann R, Weber-Nordt RM, Kanz L, Mertelsmann R.

Bone Marrow Transplant. 1996 Dec;18(6):1081-6.

PMID:
8971376
16.

Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells?

Urbano-Ispizua A, Carreras E, Marín P, Rovira M, Martínez C, Fernández-Avilés F, Xicoy B, Hernández-Boluda JC, Montserrat E.

Blood. 2001 Oct 15;98(8):2352-7.

17.

[CD34+ cell dose and hematologic recovery in allogeneic peripheral blood stem cell transplantation].

Sawada H, Wake A, Yamasaki Y, Izumi Y.

Rinsho Ketsueki. 2000 Jun;41(6):500-6. Japanese.

PMID:
10921350
18.

Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation.

Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston A, Redei I, Jurickova I, Boyer MW.

Blood. 2001 May 15;97(10):2948-56. Erratum in: Blood 2001 Sep 15;98(6):1677.

20.

Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor.

Kawano Y, Takaue Y, Watanabe A, Takeda O, Arai K, Itoh E, Ohno Y, Teshima T, Harada M, Watanabe T, Okamoto Y, Abe T, Kajiume T, Matsushita T, Ikeda K, Endo M, Kuroda Y, Asano S, Tanosaki R, Yamaguchi K, Law P, McMannis JD.

Blood. 1998 Nov 1;92(9):3123-30.

Supplemental Content

Support Center